A multicenter study of long-term outcomes of relapsing polychondritis in Iran.
Disease modifying antirheumatic drugs (DMARDs)
Immunosuppressants
Relapse
Relapsing polychondritis
Remission
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
24
04
2024
accepted:
12
07
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
17
7
2024
Statut:
epublish
Résumé
Relapsing polychondritis (RP) is a systemic immune mediated disease characterized by recurrent episodes of inflammation in various cartilage-rich areas. RP may cause extensive tissue destruction and is associated with significant morbidity and mortality. In this multicenter study, we considered the remission status and long-term outcomes of RP in patients who were followed-up in six referral rheumatology centers in Iran. Outcomes of disease was assessed by remission status and RP induced damage. A total of 29 patients with RP were examined for enrollment in the study, and 26 patients with a minimum follow-up period of 6 months were included in the RP outcome analysis. Median time to control of symptoms and sustained remission were 5 and 23 weeks, respectively. Prednisolone was discontinued in 8 (30.8%) patients and medication-free remission was achieved in 7 (23.1%) patients. Regarding the disease course, 34.6% of patients had a relapsing-remitting course, 42.3% had a monophasic course, and 23.1% had an always-active course. Despite extensive treatment with immunosuppressive medications, RP induced damage was developed in 21 (80.8%) patients. Ear deformity and osteoporosis were the most common RP induced damage. Long-term remission and medications-free remission in RP is accessible. However, RP related damage occur in majority of patients.
Identifiants
pubmed: 39020004
doi: 10.1038/s41598-024-67530-8
pii: 10.1038/s41598-024-67530-8
doi:
Substances chimiques
Prednisolone
9PHQ9Y1OLM
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
16486Subventions
Organisme : Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences
ID : CTDRC.1402.33
Informations de copyright
© 2024. The Author(s).
Références
Lahmer, T. et al. Relapsing polychondritis: An autoimmune disease with many faces. Autoimmun. Rev. 9, 540–546 (2010).
doi: 10.1016/j.autrev.2010.02.016
pubmed: 20215048
Borgia, F., Giuffrida, R., Guarneri, F. & Cannavò, S. P. Relapsing polychondritis: An updated review. Biomedicines 6, 84 (2018).
doi: 10.3390/biomedicines6030084
pubmed: 30072598
pmcid: 6164217
Horváth, A. et al. A nationwide study of the epidemiology of relapsing polychondritis. Clin. Epidemiol. 8, 211–230 (2016).
doi: 10.2147/CLEP.S91439
pubmed: 27418855
pmcid: 4934462
Arnaud, L., Mathian, A., Haroche, J., Gorochov, G. & Amoura, Z. Pathogenesis of relapsing polychondritis: A 2013 update. Autoimmun. Rev. 13(2), 90–95 (2014).
doi: 10.1016/j.autrev.2013.07.005
pubmed: 24051104
McAdam, L. P., O’Hanlan, M. A., Bluestone, R. & Pearson, C. M. Relapsing polychondritis: Prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55, 193–215 (1976).
doi: 10.1097/00005792-197605000-00001
pubmed: 775252
Damiani, J. M. & Levine, H. L. Relapsing polychondritis-report of ten cases. The Laryngoscope 89, 929–946 (1979).
doi: 10.1288/00005537-197906000-00009
pubmed: 449538
Arnaud, L. et al. The relapsing polychondritis disease activity index: Development of a disease activity score for relapsing polychondritis. Autoimmun. Rev. 12, 204–209 (2012).
doi: 10.1016/j.autrev.2012.06.005
pubmed: 22771427
Yoshida, T. et al. Risk factors for the recurrence of relapsing polychondritis. Arthritis Res. Ther. 24, 127 (2022).
doi: 10.1186/s13075-022-02810-0
pubmed: 35637525
pmcid: 9150329
Mertz, P. et al. The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. Jt. Bone Spine 86, 363–368 (2019).
doi: 10.1016/j.jbspin.2018.11.001
Michet, C. J., McKenna, C. H., Luthra, H. S. & O’Fallon, W. M. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann. Intern. Med. 104, 74–78 (1986).
doi: 10.7326/0003-4819-104-1-74
pubmed: 3484422
Kong, K. O., Vasoo, S., Tay, N. S. W. T. & Chng, H. H. Relapsing polychondritis: An oriental case series. Singap. Med. J. 44, 197–200 (2003).
Mathew, S. D., Battafarano, D. F. & Morris, M. J. Relapsing polychondritis in the department of defense population and review of the literature. Semin. Arthritis Rheum. 42, 70–83 (2012).
doi: 10.1016/j.semarthrit.2011.12.007
pubmed: 22417894
Sharma, A. et al. Relapsing polychondritis: Clinical presentations, disease activity and outcomes. Orphanet. J. Rare Dis. 9, 198 (2014).
doi: 10.1186/s13023-014-0198-1
pubmed: 25527201
pmcid: 4302515
Dion, J. et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: Analysis of a recent series of 142 patients. Arthritis Rheumatol. 68, 2992–3001 (2016).
doi: 10.1002/art.39790
pubmed: 27331771
Shimizu, J., Yamano, Y., Kawahata, K. & Suzuki, N. Nationwide cross-sectional survey of patients with relapsing polychondritis in 2019 demonstrates reduction of airway involvement compared with that in 2009. Sci. Rep. 12, 465 (2022).
doi: 10.1038/s41598-021-04493-0
pubmed: 35013504
pmcid: 8748451
Sangle, S. R. et al. Relapsing polychondritis: A single centre study in the United Kingdom. Autoimmun. Rev. 22, 103352 (2023).
doi: 10.1016/j.autrev.2023.103352
pubmed: 37146927